GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bone Biologics Corp (NAS:BBLG) » Definitions » FCF Yield %

BBLG (Bone Biologics) FCF Yield % : -202.49 (As of Jan. 18, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Bone Biologics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Bone Biologics's Trailing 12-Month Free Cash Flow is $-4.79 Mil, and Market Cap is $2.37 Mil. Therefore, Bone Biologics's FCF Yield % for today is -202.49%.

The historical rank and industry rank for Bone Biologics's FCF Yield % or its related term are showing as below:

BBLG' s FCF Yield % Range Over the Past 10 Years
Min: -839.28   Med: 0   Max: 0
Current: -202.49


BBLG's FCF Yield % is ranked worse than
96.41% of 863 companies
in the Medical Devices & Instruments industry
Industry Median: -2.29 vs BBLG: -202.49

Bone Biologics's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.


Bone Biologics FCF Yield % Historical Data

The historical data trend for Bone Biologics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bone Biologics FCF Yield % Chart

Bone Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.65 -0.19 -3.37 -111.16 -395.73

Bone Biologics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -459.17 -334.28 -240.73 -223.32 -51.23

Competitive Comparison of Bone Biologics's FCF Yield %

For the Medical Devices subindustry, Bone Biologics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bone Biologics's FCF Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bone Biologics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Bone Biologics's FCF Yield % falls into.



Bone Biologics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Bone Biologics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-9.556 / 2.4147648
=-395.73%

Bone Biologics's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-0.572 * 4 / 4.4660562
=-51.23%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bone Biologics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Bone Biologics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Bone Biologics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bone Biologics Business Description

Traded in Other Exchanges
N/A
Address
2 Burlington Woods Drive, Suite 100, Burlington, MA, USA, 01803
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
Executives
Deina H Walsh officer: Chief Financial Officer 175, MAY STREET, EDISON NJ 08837
Jeff Frelick officer: Chief Operating Officer 1 FOX RUN LANE,, LEXINGTON MA 02420
Knight Insurance Company, Ltd 10 percent owner 4751 WILSHIRE BLVD.,, SUITE 111, LOS ANGELES CA 90010
Siddhesh Rajendra Angle director 481 MONMOUTH ST, UNIT G,, JERSEY CITY NJ 07302
Erick Lucera director 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Don Hankey director, 10 percent owner, officer: Chairman of the Board 4751 WILSHIRE BLVD., SUITE 110, LOS ANGELES CA 90010
Bret Hankey director 4751 WILSHIRE BLVD. #110, LOS ANGELES CA 90010
Hankey Capital, Llc 10 percent owner 4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Don Hankey Trust 10 percent owner 4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Amir F Heshmatpour 10 percent owner 269 S. BEVERLY DRIVE, STE #1600, BEVERLY HILLS CA 90212
Musculoskeletal Transplant Foundation, Inc. director 175 MAY STREET, SUITE 300, EDISON NJ 08837
Benjamin Wu director 2740 LORAIN ROAD, SAN MARINO CA 91108
La Neve Stephen R. director, officer: CEO and President 106 MCCOOL BLVD, WEST CHESTER PA 19380
George A Oram director 12 EDGEMONT LANE, BEDMINSTER NJ 07921
Jim Delshad director 132 S. MAPLE DR., BEVERLY HILLS CA 90212